Randy D. Gascoyne
BC Cancer Agency
603 Papers
4.3K Citations
Randy D. Gascoyne is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 120, co-authored 603 publications. Previous affiliations of Randy D. Gascoyne include Queen Mary University of London & Vancouver General Hospital.
Chat about Author
Papers
The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.
Stephen Opat,Pedro Farinha,Merrill Boyle,Nathalie A. Johnson,Hilary O'Leary,James R. Cook,Raymond R. Tubbs,Lin Wang,Ryan Woods,Joseph M. Connors,Randy D. Gascoyne +10 more
TL;DR: While the non-neoplastic cellular infiltrate often constitutes only a minor fraction of the tumor mass in MCL, it appears to significantly influence response to rituximab therapy.
2
Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report
John W. Eklund,Edie Weller,Timothy M. Kuzel,Francine M. Foss,Randy D. Gascoyne,N. Abramson,J. F. Schwerkoske,Sandra J. Horning +7 more
TL;DR: This phase II trial was designed to evaluate the response rate (RR) and toxicity of DD in pts with relapsed low grade B-cell NHL, and to evaluate RR by tumor interleukin-2 receptor (IL-2R) expression.
2
CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.
Georg Lenz,R. Eric Davis,Vu N. Ngo,Lloyd T. Lam,Thaddeus C. George,George E. Wright,Sandeep S. Dave,Hong Zhao,Weihong Xu,Andreas Rosenwald,Hans Konrad Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Lisa M. Rimsza,Richard I. Fisher,Wing C. Chan,Louis M. Staudt +20 more
TL;DR: It is demonstrated that CARD11 is a bone fide oncogene in DLBCL and the findings provide a strong genetic rationale for the development of CARD11 pathway inhibitors for the therapy ofDLBCL.
2
Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494
V. Aurora,Shaoying Li,Sandra J. Horning,Daina Variakojis,Beverly P. Nelson,Maryla Krajewska,Thomas M. Habermann,Richard I. Fisher,Randy D. Gascoyne,Jane N. Winter +9 more
TL;DR: P21 is a downstream effector protein of p53 that induces cell cycle arrest by inhibiting cyclin/cyclin dependent kinase (cdK) complexes and in this prospective correlative study, it is shown that this protein acts as a ‘spatially aggregating force’ to halt the cell cycle.
2